388 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Steel Grove Capital Advisors LLC

Steel Grove Capital Advisors LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 388 shares of the company’s stock, valued at approximately $226,000.

A number of other institutional investors have also recently modified their holdings of LLY. Norges Bank acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $3,416,206,000. Moneta Group Investment Advisors LLC increased its stake in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the last quarter. Imprint Wealth LLC lifted its holdings in Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after purchasing an additional 1,747,946 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $445,944,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the sale, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. Bank of America raised their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $689.52.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $3.54 during trading on Thursday, reaching $781.72. 1,872,888 shares of the company traded hands, compared to its average volume of 3,213,223. The stock has a market capitalization of $742.76 billion, a PE ratio of 135.99, a P/E/G ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $334.58 and a 52-week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a 50 day simple moving average of $727.96 and a 200-day simple moving average of $636.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.